184 related articles for article (PubMed ID: 26475727)
1. Evolution of Hematopoietic Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
Sher T; Dispenzieri A; Gertz MA
Biol Blood Marrow Transplant; 2016 May; 22(5):796-801. PubMed ID: 26475727
[TBL] [Abstract][Full Text] [Related]
2. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.
Afrough A; Saliba RM; Hamdi A; El Fakih R; Varma A; Dinh YT; Rondon G; Cornelison AM; Shah ND; Bashir Q; Shah JJ; Hosing C; Popat U; Orlowski RZ; Champlin RE; Parmar S; Qazilbash MH
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1413-7. PubMed ID: 25842049
[TBL] [Abstract][Full Text] [Related]
3. The challenge of systemic immunoglobulin light-chain amyloidosis (Al).
Palladini G; Comenzo RL
Subcell Biochem; 2012; 65():609-42. PubMed ID: 23225018
[TBL] [Abstract][Full Text] [Related]
4. Progressive renal light chain amyloidosis with the absence of detectable free monoclonal light chains after an autologous hematopoietic stem cell transplant for amyloid light chain amyloidosis.
Roth RM; Benson D; Hebert LA; Bissell MG; Satoskar AA; Nadasdy T; Brodsky SV
Arch Pathol Lab Med; 2013 Sep; 137(9):1304-8. PubMed ID: 23991744
[TBL] [Abstract][Full Text] [Related]
5. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
6. Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation.
Comenzo RL; Wally J; Kica G; Murray J; Ericsson T; Skinner M; Zhang Y
Br J Haematol; 1999 Sep; 106(3):744-51. PubMed ID: 10468868
[TBL] [Abstract][Full Text] [Related]
7. How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis).
Chaulagain CP; Herlitz LC; Fu J; Bilani N; Lucitt C; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e826-e831. PubMed ID: 32703752
[No Abstract] [Full Text] [Related]
8. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.
Dispenzieri A; Seenithamby K; Lacy MQ; Kumar SK; Buadi FK; Hayman SR; Dingli D; Litzow MR; Gastineau DA; Inwards DJ; Micallef IN; Ansell SM; Johnston PB; Porrata LF; Patnaik MM; Hogan WJ; Gertz MA
Bone Marrow Transplant; 2013 Oct; 48(10):1302-7. PubMed ID: 23604010
[TBL] [Abstract][Full Text] [Related]
9. High dose therapy for light chain amyloidosis: can we reduce treatment related mortality further?
Dimopoulos M; Kastritis E
Leuk Lymphoma; 2008 Jan; 49(1):4-5. PubMed ID: 18203000
[No Abstract] [Full Text] [Related]
10. Toxic megacolon: a life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosis.
Hayes-Lattin BM; Curtin PT; Fleming WH; Leis JF; Stepan DE; Schubach S; Maziarz RT
Bone Marrow Transplant; 2002 Sep; 30(5):279-85. PubMed ID: 12209349
[TBL] [Abstract][Full Text] [Related]
11. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
[TBL] [Abstract][Full Text] [Related]
12. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation.
Leung N; Kumar SK; Glavey SV; Dispenzieri A; Lacy MQ; Buadi FK; Hayman SR; Dingli D; Kapoor P; Zeldenrust SR; Russell SJ; Lust JA; Hogan WJ; Rajkumar SV; Gastineau DA; Kourelis TV; Lin Y; Gonsalves WI; Go RS; Gertz MA
Nephrol Dial Transplant; 2016 Aug; 31(8):1284-9. PubMed ID: 26627634
[TBL] [Abstract][Full Text] [Related]
13. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.
Cordes S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Kumar SK; Hogan WJ; Gertz MA
Cancer; 2012 Dec; 118(24):6105-9. PubMed ID: 22707405
[TBL] [Abstract][Full Text] [Related]
14. How we treat systemic light-chain amyloidosis.
Chaulagain CP; Comenzo RL
Clin Adv Hematol Oncol; 2015 May; 13(5):315-24. PubMed ID: 26352777
[TBL] [Abstract][Full Text] [Related]
15. Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis.
Schönland SO; Dreger P; de Witte T; Hegenbart U
Bone Marrow Transplant; 2012 Jul; 47(7):895-905. PubMed ID: 21785469
[TBL] [Abstract][Full Text] [Related]
16. New and developing therapies for AL amyloidosis.
Zumbo G; Sadeghi-Alavijeh O; Hawkins PN; Fontana M
Expert Opin Pharmacother; 2017 Feb; 18(2):139-149. PubMed ID: 28002971
[TBL] [Abstract][Full Text] [Related]
17. Decrease of B-type natriuretic peptide to less than 200 pg/mL predicts longer survival in cardiac immunoglobulin light chain amyloidosis.
Ishiguro K; Hayashi T; Igarashi T; Maruyama Y; Ikeda H; Ishida T; Shinomura Y
Int J Hematol; 2015 Aug; 102(2):200-4. PubMed ID: 26016720
[TBL] [Abstract][Full Text] [Related]
18. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
Comenzo RL
Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin light chain amyloidosis and the kidney.
Gertz MA; Lacy MQ; Dispenzieri A
Kidney Int; 2002 Jan; 61(1):1-9. PubMed ID: 11786079
[TBL] [Abstract][Full Text] [Related]
20. Treatment of immunoglobulin light chain (primary or AL) amyloidosis.
Gertz MA; Buadi FK; Hayman SR
Oncology (Williston Park); 2011 Jun; 25(7):620-6. PubMed ID: 21888261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]